{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:16:03Z","timestamp":1790691363165,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer Oncology Australia"},{"DOI":"10.13039\/501100001170","name":"The Cancer Council Western Australia","doi-asserted-by":"crossref","award":["1028735"],"award-info":[{"award-number":["1028735"]}],"id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council of Australia","award":["458543"],"award-info":[{"award-number":["458543"]}]},{"name":"the Insurance Commission of Western Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1093\/annonc\/mdv387","type":"journal-article","created":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T01:44:15Z","timestamp":1442627055000},"page":"2483-2490","source":"Crossref","is-referenced-by-count":94,"title":["A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"26","author":[{"given":"A.K.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Creaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Musk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Turlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.W.S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv387_bb0010","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv387_bb0015","doi-asserted-by":"crossref","first-page":"e23033","DOI":"10.4161\/onci.23033","article-title":"Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors","volume":"2","author":"Vonderheide","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdv387_bb0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1078-0432.CCR-06-1893","article-title":"Prospect of targeting the CD40 pathway for cancer therapy","volume":"13","author":"Vonderheide","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv387_bb0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"Ruter","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdv387_bb0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv387_bb0035","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv387_bb0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv387_bb0045","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/mdv387_bb0050","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv387_bb0055","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv387_bb0060","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.0000139859.68513.FC","article-title":"Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells","volume":"110","author":"Damas","year":"2004","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mdv387_bb0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv387_bb0070","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdv387_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cellimm.2006.02.005","article-title":"B cells as antigen presenting cells","volume":"238","author":"Rodriguez-Pinto","year":"2005","journal-title":"Cell Immunol"},{"key":"10.1093\/annonc\/mdv387_bb0080","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1093\/annonc\/mdv387_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1479-5876-7-93","article-title":"Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation","volume":"7","author":"Carpenter","year":"2009","journal-title":"J Transl Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419357187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/12\/2483\/16700126\/mdv387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:54:26Z","timestamp":1624521266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419357187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0923753419357187"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv387","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}